Mathew T. Pletcher is a member of the Scientific Advisory Board at 64x Bio. He currently serves as the Chief Scientific Officer for Weaver Biosciences, which is developing a platform for targeted epigenetic editing. He is also the Founder of RDH12 Fund for Sight, a non-profit devoted to the development of a gene therapy for Leber Congenital Amaurosis, and a Board Member of Odylia Therapeutics, a non-profit focused on developing gene therapies for ultra-rare diseases. He also holds an adjunct faculty appointment with the University of North Carolina.

‍

Mathew was formerly the Chief Scientific Officer of Kisbee Therapeutics, which focused on Apolipoprotein biology. Prior to that, he was the SVP and Division Head for Gene Therapy Research and Technical Operations at Astellas Gene Therapies. Overseeing a group of ~350 individuals, his team was responsible for leading the pre-clinical gene therapy portfolio and all gene therapy manufacturing activities from project initiation through commercialization. Prior to that, he was the Head of Rare Disease for Roche, directing early development and research activities for rare neuromuscular, neurodevelopmental, ophthalmological, neurodegenerative, and hematopoietic diseases and helped support the approval of Risdiplam (Evrysdi) for Spinal Muscular Atrophy. Mathew began his career in industry at Pfizer, ultimately serving as Director of Medical Genetics for the Rare Disease Research Unit. Prior to that, he established a lab focused on the genetics of antidepressant efficacy and mouse models of autism as well as building and directing the Genetics and Genomics Core Facility at Scripps Research Institute.

‍

Mathew earned his PhD in Human Genetics from the Johns Hopkins School of Medicine and completed a postdoctoral fellowship at the Genomics Institute of the Novartis Research Foundation, where he published the first haplotype map of mouse inbred strains.